Literature DB >> 25977585

Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation.

Elmina Mammadova-Bach1, Véronique Ollivier2, Stéphane Loyau2, Mathieu Schaff1, Bénédicte Dumont2, Rémi Favier3, Geneviève Freyburger4, Véronique Latger-Cannard5, Bernhard Nieswandt6, Christian Gachet1, Pierre H Mangin1, Martine Jandrot-Perrus2.   

Abstract

Fibrin, the coagulation end product, consolidates the platelet plug at sites of vascular injury and supports the recruitment of circulating platelets. In addition to integrin αIIbβ3, another as-yet-unidentified receptor is thought to mediate platelet interaction with fibrin. Platelet glycoprotein VI (GPVI) interacts with collagen and several other adhesive macromolecules. We evaluated the hypothesis that GPVI could be a functional platelet receptor for fibrin. Calibrated thrombin assays using platelet-rich plasma (PRP) showed that tissue factor-triggered thrombin generation was impaired in GPVI-deficient patients and reduced by the anti-GPVI Fab 9O12. Assays on reconstituted PRP and PRP from fibrinogen-deficient patients revealed a fibrinogen-dependent enhancement of thrombin generation, which relied on functional GPVI. The effect of GPVI was found to depend on fibrin polymerization. A binding assay showed a specific interaction between GPVI-Fc and fibrin, inhibited by the Fab 9O12. This Fab also reduced platelet adhesion to fibrin at low (300 s(-1)) and high (1500 s(-1)) wall shear rates. Platelets adherent to fibrin displayed shape change, exposure of procoagulant phospholipids, and the formation of small clots. When hirudinated blood was perfused at 1500 s(-1) over preformed fibrin-rich clots, the Fab 9O12 decreased the recruitment of platelets by up to 85%. This study identifies GPVI as a platelet receptor for polymerized fibrin with 2 major functions: (1) amplification of thrombin generation and (2) recruitment of circulating platelets to clots. These so-far-unrecognized properties of GPVI confer on it a key role in thrombus growth and stabilization.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25977585     DOI: 10.1182/blood-2015-02-629717

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  66 in total

1.  TC21/RRas2 regulates glycoprotein VI-FcRγ-mediated platelet activation and thrombus stability.

Authors:  S Janapati; J Wurtzel; C Dangelmaier; B K Manne; D Bhavanasi; J C Kostyak; S Kim; M Holinstat; S P Kunapuli; L E Goldfinger
Journal:  J Thromb Haemost       Date:  2018-06-08       Impact factor: 5.824

Review 2.  Platelet "first responders" in wound response, cancer, and metastasis.

Authors:  David G Menter; Scott Kopetz; Ernest Hawk; Anil K Sood; Jonathan M Loree; Paolo Gresele; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

3.  Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.

Authors:  Phillip L R Nicolson; Craig E Hughes; Stephanie Watson; Sophie H Nock; Alexander T Hardy; Callum N Watson; Samantha J Montague; Hayley Clifford; Aarnoud P Huissoon; Jean-Daniel Malcor; Mark R Thomas; Alice Y Pollitt; Michael G Tomlinson; Guy Pratt; Steve P Watson
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

4.  Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects.

Authors:  Constance C F M J Baaten; Frauke Swieringa; Tomasz Misztal; Tom G Mastenbroek; Marion A H Feijge; Paul E Bock; Marjo M P C Donners; Peter W Collins; Renhao Li; Paola E J van der Meijden; Johan W M Heemskerk
Journal:  Blood Adv       Date:  2018-09-25

Review 5.  Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation.

Authors:  Paul Saultier; Sarah Szepetowski; Matthias Canault; Céline Falaise; Marjorie Poggi; Pierre Suchon; Vincent Barlogis; Gérard Michel; Stéphane Loyau; Martine Jandrot-Perrus; Jean-Claude Bordet; Marie-Christine Alessi; Hervé Chambost
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

6.  Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI.

Authors:  Samantha J Montague; Céline Delierneux; Christelle Lecut; Nathalie Layios; Robert J Dinsdale; Christine S-M Lee; Natalie S Poulter; Robert K Andrews; Peter Hampson; Christopher M Wearn; Nathalie Maes; Jonathan Bishop; Amy Bamford; Chris Gardiner; Woei Ming Lee; Tariq Iqbal; Naiem Moiemen; Steve P Watson; Cécile Oury; Paul Harrison; Elizabeth E Gardiner
Journal:  Blood Adv       Date:  2018-02-13

7.  Interspecies differences in protein expression do not impact the spatiotemporal regulation of glycoprotein VI mediated activation.

Authors:  Joanne L Dunster; Amanda J Unsworth; Alexander P Bye; Elizabeth J Haining; Marcin A Sowa; Ying Di; Tanya Sage; Chiara Pallini; Jeremy A Pike; Alexander T Hardy; Bernhard Nieswandt; Ángel García; Steve P Watson; Natalie S Poulter; Jonathan M Gibbins; Alice Y Pollitt
Journal:  J Thromb Haemost       Date:  2019-12-06       Impact factor: 5.824

Review 8.  Functional significance of the platelet immune receptors GPVI and CLEC-2.

Authors:  Julie Rayes; Steve P Watson; Bernhard Nieswandt
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

9.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

10.  Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.

Authors:  Oliver Borst; Patrick Münzer; Nada Alnaggar; Sascha Geue; Roland Tegtmeyer; Dominik Rath; Michal Droppa; Peter Seizer; Stefan Heitmeier; Johan W M Heemskerk; Lisa K Jennings; Robert F Storey; Dominick J Angiolillo; Bianca Rocca; Henri Spronk; Hugo Ten Cate; Meinrad Gawaz; Tobias Geisler
Journal:  Blood Adv       Date:  2018-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.